Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20694959 | 0.98 | GPBAR1 (0.43) | GPBAR1TLR8TSHRLTA4HCYSLTR2 | |
| SCHEMBL2253966 | 0.94 | LTA4H (0.41) | GPBAR1TLR8LTA4HCYSLTR2CYSLTR1 | |
| SCHEMBL1389303 | 0.89 | GPBAR1 (0.40) | GPBAR1TLR8CYSLTR2CYSLTR1MCHR1 | |
| SCHEMBL6283599 | 0.86 | MCHR1 (0.41) | GPBAR1TLR8TSHRLTA4HCYSLTR2 | |
| SCHEMBL2458064 | 0.86 | MCHR1 (0.41) | GPBAR1TLR8TSHRLTA4HCYSLTR2 | |
| SCHEMBL2456698 | 0.86 | MCHR1 (0.41) | GPBAR1TLR8TSHRLTA4HCYSLTR2 | |
| SCHEMBL1396371 | 0.84 | LTA4H (0.41) | GPBAR1TLR8TSHRLTA4HCYSLTR2 | |
| SCHEMBL1127483 | 0.83 | MAPK1 (0.38) | TLR8LTA4H | |
| SCHEMBL2256189 | 0.80 | L3MBTL1 (0.41) | GPBAR1TLR8TSHRLTA4HCYSLTR2 | |
| SCHEMBL2252881 | 0.76 | KCNH2 (0.39) | TLR8CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220069354-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2022-03-03 | — | — | US | disclosed |
| EP-3904337-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | FUJIFILM Wako Pure Chemical Corporation (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3439097-B1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-10727534-B2 | Electrolyte solution containing magnesium ions | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2020-07-28 | — | — | US | disclosed |
| WO-2020138377-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | 富士フイルム和光純薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| US-20190131657-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3439097-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | FUJIFILM Wako Pure Chemical Corporation (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10727534-B2 | Electrolyte solution containing magnesium ions | MLX, PRDX1, PRDX6 | GPBAR1 242/4885TLR8 2468/4885TSHR 2008/4885 |
| US-20220069354-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | SLC26A3, PRDX4, PRDX2 | GPBAR1 117/4885TLR8 4273/4885TSHR 345/4885 |
| US-20190131657-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | MLX, PRDX1, PRDX6 | GPBAR1 242/4885TLR8 2468/4885TSHR 2008/4885 |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | GPBAR1 971/4885TLR8 2738/4885TSHR 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.